2011
Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients
Vergara-Rodriguez P, Tozzi MJ, Botsko M, Nandi V, Altice F, Egan JE, O'Connor PG, Sullivan LE, Fiellin DA. Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s62-s67. PMID: 21317596, DOI: 10.1097/qai.0b013e31820a820f.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneOpioid-dependent patientsMedian aspartate aminotransferasePharmacodynamic interactionsAspartate aminotransferaseBup/ALT valuesAlanine aminotransferaseBUP/NXOpioid-dependent HIVProspective cohort studyHepatic safetyHepatitis CCohort studyHepatic toxicityHIVPatientsAtazanavirNaloxonePrior reportsExposure measuresSignificant decreaseAminotransferaseSignificant changesTreatment
2002
The Health–Related Effects of Alcohol Use in Older Persons: A Systematic Review
Reid M, Boutros N, O'Connor P, Cadariu A, Concato J. The Health–Related Effects of Alcohol Use in Older Persons: A Systematic Review. Substance Abuse 2002, 23: 149-164. PMID: 12444348, DOI: 10.1080/08897070209511485.Peer-Reviewed Original ResearchConceptsCause mortalityCognitive impairmentExposure statusFunctional disabilityAlcohol useOlder adultsFunctional impairmentMiddle-aged adult populationParticipants 60 yearsYears of ageEnglish-language studiesExposure-outcome associationsImportant confounding factorsHealth-related effectsEffects of alcoholMagnitude of riskCohort studySubstantial morbidityPercentage of studiesFormer drinkersProspective studyMean ageAlcohol exposureMethodologic qualityOutcome measuresThe Health-Related Effects of Alcohol Use in Older Persons: A Systematic Review
Reid MC, Boutros NN, O'Connor PG, Cadariu A, Concato J. The Health-Related Effects of Alcohol Use in Older Persons: A Systematic Review. Substance Abuse 2002, 23: 149-164. DOI: 10.1023/a:1019896822588.Peer-Reviewed Original ResearchConceptsCause mortalityCognitive impairmentExposure statusFunctional disabilityAlcohol useOlder adultsFunctional impairmentMiddle-aged adult populationParticipants 60 yearsYears of ageEnglish-language studiesExposure-outcome associationsImportant confounding factorsHealth-related effectsEffects of alcoholMagnitude of riskCohort studySubstantial morbidityPercentage of studiesFormer drinkersProspective studyMean ageAlcohol exposureMethodologic qualityOutcome measures
1999
Tuberculosis chemoprophylaxis using a liquid isoniazid‐methadone admixture for drug users in methadone maintenance
O'Connor PG, Shi JM, Henry S, Durante AJ, Friedman L, Selwyn PA. Tuberculosis chemoprophylaxis using a liquid isoniazid‐methadone admixture for drug users in methadone maintenance. Addiction 1999, 94: 1071-1075. PMID: 10707445, DOI: 10.1046/j.1360-0443.1999.947107112.x.Peer-Reviewed Original ResearchConceptsMethadone maintenanceTuberculosis chemoprophylaxisDrug usersMedian durationDaily doseOpioid-dependent drug usersProspective cohort studyMethadone maintenance programDrug treatment programsCompleting therapyINH chemoprophylaxisINH prophylaxisCohort studyEligible subjectsINH therapyCommon reasonChemoprophylaxisTherapyVitamin B6Treatment programMethadoneIsoniazidSubjectsINHDuration
1991
Social and clinical features as predictors of outcome in outpatient alcohol withdrawal
O’Connor P, Gottlieb L, Kraus M, Segal S, Horwitz R. Social and clinical features as predictors of outcome in outpatient alcohol withdrawal. Journal Of General Internal Medicine 1991, 6: 312-316. PMID: 1890501, DOI: 10.1007/bf02597427.Peer-Reviewed Original ResearchConceptsWithdrawal symptom severityAlcohol withdrawal syndromeTreatment failureSymptom severityOutpatient managementAlcohol withdrawalClinical featuresWithdrawal syndromeOutpatient alcohol treatment programProspective observational cohort studyHigh-risk patientsObservational cohort studyTreatment failure rateMedical insurance statusPredictors of outcomeAlcohol treatment programsLow symptom groupCohort studyDrug therapyInsurance statusClinical trialsPatient featuresSociodemographic featuresPatientsTreatment program